Atypical Antipsychotic Medications: Use In Pediatric Patients

This document was released by the Centers for Medicare & Medicaid Services (CMS) Medicaid Integrity Group (MIG) in July of 2014. It identifies issues with the utilization of the atypical antipsychotic drug therapy class. The MIG identifies that some providers may have prescribed atypical antipsychotics outside of FDA-approved product labeling for indication, age, dosage, or duration of therapy . . .